Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Results from a cohort study of 745 patients with castration-resistant prostate cancer with bone metastases receiving first-line abiraterone acetate with prednisone demonstrated that the use of concomitant bone resorption inhibitors (BRIs) was associated with better overall survival (OS; 31.8 months) compared to patients who didn't receive BRIs (23.0 months; HR 0.65; 95% CI, 0.54-0.79; P < .001). In the BRI cohort, patients with high-volume disease experienced greater OS than those with low-volume disease (33.6 vs. 19.7 months, respectively; HR 0.51; 95% CI, 0.38-0.68; P < .001).